• Most Popular
  • Most Shared

Research and Markets: Report on Israel's Pharmaceutical Market: Understand The Key Drivers In The Pharmaceutical Market And Have Access To A Wealth Of Statistical Data

Tue Nov 10, 2009 4:35am EST
DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/a57a5f/the_pharmaceutical) has
announced the addition of the "The Pharmaceutical Market: Israel" report to
their offering. 

The Israeli pharmaceutical market grew strongly in the 1990s, averaging around
10% per annum, although this has slowly been tempered to the 5.3% estimated for
2008, partly due to the economic slow-down. This report is ideal for executives
wanting to understand the key drivers in the pharmaceutical market and have
access to a wealth of statistical data, including five-year market projections.
Included with the report are 3 free quarterly updated outlook reports, enabling
you to keep up to date with market developments for a year. 

Israel borders Lebanon, Syria, Jordan, Egypt and the Mediterranean Sea. Lying
within its borders are areas that the Palestinians claim as their own; the
threat of terrorism dominates the political landscape. 

Israel has the largest medical device market in the Middle East region and this
is set to grow at an attractive rate of 6.1% in the medium term. Much of the
market, at over 80%, is supplied by imports, and a significant portion of these
in value terms are dominated by "high-end" products falling under the diagnostic
imaging apparatus category. 

In terms of expenditure, Israel spends around 8.0% of total GDP on healthcare,
and per capita spending rates are considered high by regional and world
standards. Much of spending is in the public sector and the government has made
allowances in recent years to expand the number of services and treatment
offered by public health insurance programmes. The country also has a rapidly
growing elderly demographic that is contributing to rising healthcare costs. 

As well as being a political ally, the US is one of the leading suppliers of
imports, along with Germany; the two countries shipped a combined total of
US$292.1 million, equal to just under half of total imports in 2007. The EU and
the US are vital trade partners for Israel, as the country is isolated from its
Arab neighbours and conducts virtually no trade with them. 

Thanks to a substantial domestic production capacity, Israel exported over US$1
billion worth of goods in 2007, primarily diagnostic imaging equipment, which
was responsible for over half the total. 

Espicom estimates the medical device market in Israel to be worth US$661 million
in 2009, equal to US$89 per capita. The market is expected to experience annual
growth of 6.1%, taking it to US$889 million, or US$110 per capita, by 2014. 

Key Topics Covered:

* Executive Summary 
* Pharmaceutical Market 
* Key National Data Projections 
* Geography 
* Political Overview 
* Economic Overview 
* Population 
* Demographic Indicators 
* Mortality 
* Morbidity 
* Organisation & Administration 
* Health Expenditure 
* Hospital Services 
* Ambulatory Care 
* Medical Personnel 
* Regulatory Environment 
* Distribution Channels 
* Pharmaceutical Imports 
* Domestic Production & Exports 
* Directory

Companies Mentioned:

* Bio-Dar Ltd 
* Clal Pharmaceutical Resources L.P 
* CTS Ltd 
* Dexxon Ltd 
* Kamada Ltd 
* Karmat Ltd 
* Koffolk Ltd 
* Perrigo Israel Pharmaceuticals Ltd 
* Rafa Laboratories Ltd 
* Savient Pharmaceuticals 
* Teva Pharmaceutical Industries Ltd 
* Trima-Israel Pharmaceutical Products Ltd

For more information visit
http://www.researchandmarkets.com/research/a57a5f/the_pharmaceutical

Source: Espicom Business Intelligence Ltd

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716 

Copyright Business Wire 2009



More from Reuters

Photo

Tech solutions to climate change

Experts say there is no single answer to solving global warming, but a handful of technologies could be promising. Check out some of the candidates and join the debate.  Full Article 

    Kenneth Feinberg, special master of executive compensation in the Troubled Asset Relief Program at the Treasury, speaks in Washington November 2, 2009. REUTERS/Joshua Roberts

    Pay cuts, round two

    Pay czar Kenneth Feinberg cracked the whip in his latest round of compensation rulings, slimming the salaries of top-tier earners at bailed-out companies.  Full Article 

     The share price index DAX board is seen in front of an emergency exit sign at Frankfurt's stock exchange, October 8, 2008. REUTERS/Kai Pfaffenbach

    "Deflation is with us"

    Fear of the market abyss has faded for investors, but another fear is lurking on the horizon, if not already here.  Full Article